Table 4 |
|||||||||
|
Protein marker associations between tumors with/without Amp13q34, CUL4A expression, or TFDP1 expression |
|||||||||
|
Clinical & IHC feature |
13q34 Amplification |
CUL4A expression |
TFDP1 expression |
||||||
|
|
|
|
|||||||
|
Absence |
Presence |
P |
Negative |
Positive |
P |
Negative |
Positive |
P |
|
|
|
|||||||||
|
Grade |
|||||||||
|
1 |
42 (32.1) |
0 |
0.002* |
26 (40.6) |
10 (19.2) |
0.010* |
12 (32.4) |
27 (33.3) |
NS* |
|
2 |
40 (30.5) |
0 |
19 (29.7) |
13 (25.0) |
11 (29.7) |
22 (27.2) |
|||
|
3 |
49 (37.4) |
8 (100) |
19 (29.7) |
29 (55.8) |
14 (37.8) |
32 (39.5) |
|||
|
|
|||||||||
|
ER |
|||||||||
|
Negative |
56 (35.4) |
8 (88.9) |
0.002 |
30 (36.6) |
29 (48.3) |
NS |
24 (46.2) |
35 (38.0) |
NS |
|
Positive |
102 (64.6) |
1 (11.1) |
52 (63.4) |
31 (51.7) |
28 (53.8) |
57 (62.0) |
|||
|
|
|||||||||
|
PR |
|||||||||
|
Negative |
68 (47.2) |
8 (88.9) |
0.018 |
30 (43.5) |
37 (62.7) |
0.034 |
20 (48.8) |
47 (52.3) |
NS |
|
Positive |
76 (52.8) |
1 (11.1) |
39 (56.5) |
22 (37.3) |
21 (51.2) |
42 (47.7) |
|||
|
|
|||||||||
|
BCL2 |
|||||||||
|
Negative |
82 (56.9) |
8 (88.9) |
0.082 |
37 (53.6) |
42 (71.2) |
0.047 |
29 (70.7) |
52 (58.4) |
NS |
|
Positive |
62 (43.1) |
1 (11.1) |
32 (46.4) |
17 (28.8) |
12 (29.3) |
37 (41.6) |
|||
|
|
|||||||||
|
Ki-67 |
|||||||||
|
0-5% |
68 (47.2) |
1 (11.1) |
< 0.001* |
35 (50.7) |
22 (37.3) |
NS* |
22 (53.7) |
35 (39.3) |
NS* |
|
6-25% |
56 (38.9) |
1 (11.1) |
24 (34.8) |
20 (33.9) |
13 (31.7) |
32 (36.0) |
|||
|
> 25% |
20 (13.9) |
7 (77.8) |
10 (14.5) |
17 (28.8) |
6 (14.6) |
22 (24.7) |
|||
|
|
|||||||||
|
EGFR |
|||||||||
|
Negative |
181 (90.0) |
4 (40.0) |
< 0.001 |
122 (91.7) |
57 (80.3) |
0.024 |
94 (91.3) |
89 (85.6) |
NS |
|
Positive |
20 (10.0) |
6 (60.0) |
11 (8.3) |
14 (19.7) |
9 (8.7) |
15 (14.4) |
|||
|
|
|||||||||
|
Cadherin P |
|||||||||
|
Negative |
128 (92.1) |
3 (33.3) |
< 0.001 |
63 (95.5) |
46 (79.3) |
0.011 |
37 (94.9) |
74 (86.0) |
NS |
|
Positive |
11 (7.9) |
6 (66.6) |
3 (4.5) |
12 (20.7) |
2 (5.1) |
12 (14.0) |
|||
|
|
|||||||||
|
G-Catenin |
|||||||||
|
Negative |
106 (79.1) |
4 (44.4) |
0.031 |
59 (86.8) |
43 (75.4) |
NS |
36 (90.0) |
69 (78.4) |
NS |
|
Positive |
28 (20.9) |
5 (55.5) |
9 (13.2) |
14 (24.6) |
4 (10.0) |
19 (21.6) |
|||
|
|
|||||||||
|
Cyclin D1 |
|||||||||
|
Negative |
67 (47.2) |
8 (88.9) |
0.018 |
32 (47.1) |
27 (46.6) |
NS |
17 (42.5) |
42 (47.7) |
NS |
|
Positive |
75 (52.8) |
1 (11.1) |
36 (52.9) |
31 (53.4) |
23 (57.5) |
46 (52.3) |
|||
|
|
|||||||||
|
Cyclin E |
|||||||||
|
Negative |
103 (72.5) |
2 (22.2) |
0.004 |
50 (73.5) |
34 (58.6) |
0.090 |
32 (80.0) |
53 (60.2) |
0.043 |
|
Positive |
39 (27.5) |
7 (77.8) |
18 (26.5) |
24 (41.4) |
8 (20.0) |
35 (39.8) |
|||
|
|
|||||||||
|
Cyclin B1 |
|||||||||
|
Negative |
111 (80.4) |
4 (44.4) |
0.024 |
57 (86.4) |
40 (70.2) |
0.045 |
37 (92.5) |
61 (72.6) |
0.010 |
|
Positive |
27 (19.6) |
5 (55.6) |
9 (13.6) |
17 (29.8) |
3 (7.5) |
23 (27.4) |
|||
|
|
|||||||||
|
RB |
|||||||||
|
Negative |
33 (23.9) |
6 (66.7) |
0.011 |
12 (18.2) |
14 (24.1) |
NS |
11 (27.5) |
15 (17.4) |
NS |
|
Positive |
105 (76.1) |
3 (33.3) |
54 (81.8) |
44 (75.9) |
29 (72.5) |
71 (82.6) |
|||
|
|
|||||||||
|
E2F6 |
|||||||||
|
Negative |
89 (64.5) |
4 (44.4) |
NS |
39 (59.1) |
38 (66.7) |
NS |
30 (75.0) |
47 (56.0) |
0.049 |
|
Positive |
49 (35.5) |
5 (55.6) |
27 (40.9) |
19 (33.3) |
10 (25.0) |
37 (44.0) |
|||
|
|
|||||||||
|
P16 |
|||||||||
|
Negative |
53 (39.0) |
7 (77.8) |
0.033 |
24 (36.9) |
30 (51.7) |
NS |
23 (59.0) |
31 (36.0) |
0.020 |
|
Positive |
83 (61.0) |
2 (22.2) |
41 (63.1) |
28 (48.3) |
16 (41.0) |
55 (64.0) |
|||
|
|
|||||||||
|
SKP2 |
|||||||||
|
Negative |
66 (46.8) |
1 (11.1) |
0.043 |
40 (58.8) |
22 (37.9) |
0.021 |
24 (60.0) |
40 (46.0) |
NS |
|
Positive |
75 (53.2) |
8 (88.9) |
28 (41.2) |
36 (62.1) |
16 (40.0) |
47 (54.0) |
|||
|
|
|||||||||
|
Survivin |
|||||||||
|
Negative |
97 (70.8) |
1 (11.1) |
0.001 |
49 (72.1) |
35 (61.4) |
NS |
30 (75.0) |
57 (64.8) |
NS |
|
Positive |
40 (29.2) |
8 (88.9) |
19 (27.9) |
22 (38.6) |
10 (25.0) |
31 (35.2) |
|||
|
|
|||||||||
|
CK5 |
|||||||||
|
Negative |
133 (86.4) |
3 (33.3) |
0.001 |
74 (90.2) |
43 (72.9) |
0.011 |
42 (82.4) |
77 (82.8) |
NS |
|
Positive |
21 (13.6) |
6 (66.6) |
8 (9.8) |
16 (27.1) |
9 (17.6) |
16 (17.2) |
|||
|
|
|||||||||
|
CK8 |
|||||||||
|
Negative |
28 (19.9) |
7 (77.8) |
0.001 |
12 (17.6) |
17 (29.3) |
NS |
7 (17.5) |
24 (27.0) |
NS |
|
Positive |
113 (80.1) |
2 (22.2) |
56 (82.4) |
41 (70.7) |
33 (82.5) |
65 (73.0) |
|||
|
|
|||||||||
|
Vimentin |
|||||||||
|
Negative |
109 (79.0) |
3 (33.3) |
0.006 |
53 (77.9) |
41 (70.7) |
NS |
32 (80.0) |
63 (72.4) |
NS |
|
Positive |
29 (21.0) |
6 (66.6) |
15 (22.1) |
17 (29.3) |
8 (20.0) |
24 (27.6) |
|||
|
|
|||||||||
|
ER = Estrogen Receptor; PR = Progesterone Receptor; CK = cytokeratin. RB = retinoblastoma gene protein. Markers statistically significant in at least one of the tumor group comparisons are shown. P values ≤ 0.10 are depicted, in bold those statistically significant (P ≤ 0.05). NS = non-significant. P values were calculated by Fisher's Exact Test, except histological grade and Ki-67 analyses that were done with Pearson's Chi square (*). Other markers were also analyzed (such as HER2) but gave no significant associations. |
|||||||||
|
Melchor et al. Breast Cancer Research 2009 11:R86 doi:10.1186/bcr2456 |
|||||||||
